Listed by the USPTO as KETCHAM, KAREN A
Tech Center 1600 • Art Units: 1611 1614
This examiner grants 20% of resolved cases
KETCHAM, KAREN A is a USPTO patent examiner in tech center 1600 and art unit 1611. The record includes 56 resolved cases, an allowance rate of 19.6%, and a median of 1278 days to allowance. Interview lift is 37.2%, indicating that examiner interviews may be particularly useful for focusing claim and prior-art discussions within a record showing a limited allowance rate.
L'Oréal, UPL Corporation Limited, and The Procter & Gamble Company are the leading companies. The leading firms are CANTOR COLBURN LLP - UPL LIMITED, SUGHRUE MION, PLLC, and Buchanan Ingersoll & Rooney PC. Because the resolved-case base is limited, practitioners should rely on application-specific analysis, prepare carefully for interviews, and plan for the recorded duration before deciding how much claim scope to amend.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17549989 | Stable Skin Care Emulsion and Methods of Using the Same | Final Rejection | The Procter & Gamble Company |
| 17640220 | MICROBIOCIDAL USE | Final Rejection | DSM IP ASSETS B.V. |
| 18283490 | SPREADING AGENT, FERTILIZER COMPOSITION AND AGRICULTURAL CHEMICAL COMPOSITION | Non-Final OA | Resonac Corporation |
| 17436104 | Rhamnolipids as deposition aid | Non-Final OA | Evonik Operations GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy19.6% of resolved applications examined by Karen A Ketcham were allowed (56 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +37.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Karen A Ketcham took 1,278 days on average from filing to allowance.
Karen A Ketcham examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
